Search

CytomX Therapeutics Inc

Открыт

СекторЗдравоохранение

3.41 3.02

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.2800000000000002

Макс.

3.43

Ключевые показатели

By Trading Economics

Доход

-2.4M

-21M

Продажи

-8.8M

1.4M

P/E

Средняя по отрасли

22.5

57.366

Прибыль на акцию

-0.09

Рентабельность продаж

-1,457.405

Сотрудники

69

EBITDA

-2.4M

-20M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+285.54% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

27M

717M

Предыдущая цена открытия

0.39

Предыдущая цена закрытия

3.41

Новостные настроения

By Acuity

50%

50%

160 / 340 Рейтинг в Healthcare

CytomX Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

25 авг. 2026 г., 19:56 UTC

CytomX Therapeutics is trading higher amid positive market conditions and lower crude oil prices, which have decreased treasury yields and boosted investor sentiment.

24 авг. 2026 г., 19:26 UTC

CytomX Therapeutics is trading higher, reflecting gains since Friday's close. Earlier, shares peaked with a gain before pulling back to a modest advance.

21 авг. 2026 г., 19:46 UTC

CytomX Therapeutics Inc. is gaining during Friday's session, despite earlier volatility. No specific company news was identified to explain today's price movement.

20 авг. 2026 г., 21:01 UTC

CytomX Therapeutics Inc shares are higher in after-market hours, reflecting unusual trading activity. The stock is positioned around the midpoint of its one-month range.

19 авг. 2026 г., 20:02 UTC

CytomX Therapeutics is trading higher during Wednesday's session, continuing a strong upward move since Tuesday's close amid notable volatility.

14 авг. 2026 г., 19:36 UTC

Social Media

CytomX Therapeutics is higher as social media highlights its undervaluation, with a suggested price target of $6-7 ahead of year-end data releases.

13 авг. 2026 г., 22:01 UTC

CytomX Therapeutics shares are higher in after-market trading, supported by broader market strength and a record closing high for the S&P 500.

12 авг. 2026 г., 19:46 UTC

CytomX Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close, supported by positive sentiment from the recent inflation report.

11 авг. 2026 г., 23:21 UTC

CytomX Therapeutics Inc. shares are higher in after-market trading, reaching 1.45% above Tuesday's close amid strong performance relative to its moving average.

10 авг. 2026 г., 23:31 UTC

CytomX Therapeutics Inc shares are lower in after-market hours after earlier volatility. Broader market sentiment remains cautious amid geopolitical tensions in the Strait of Hormuz.

7 авг. 2026 г., 19:16 UTC

Social Media
News

CytomX Therapeutics expands collaboration with Regeneron on immunotherapies and updates on Varseta-M program, boosting sentiment amid a rising Biotechnology sector.

6 авг. 2026 г., 22:02 UTC

Social Media
News

CytomX Therapeutics shares declined in after-market hours following a significant revenue miss of $1.418 million against expectations of $12.308 million.

31 июл. 2026 г., 20:06 UTC

CytomX Therapeutics Inc shares declined sharply during Friday's session, reversing earlier gains and trading well below the 20-day moving average. No specific news was identified.

29 июл. 2026 г., 19:47 UTC

CytomX Therapeutics shares are lower as traders await the Federal Reserve's interest rate decision, contributing to mixed performance across major U.S. indices.

28 июл. 2026 г., 17:46 UTC

CytomX Therapeutics shares are lower today, reflecting a broader cautious tone across Asian markets. The stock remains near its one-month low.

27 июл. 2026 г., 23:26 UTC

CytomX Therapeutics shares are higher in after-market hours, though no specific news was identified. Broader positive sentiment in European indices may be influencing investors.

21 июл. 2026 г., 19:56 UTC

CytomX Therapeutics Inc shares are lower today, continuing a downward trend. The stock remains significantly below its 20-day moving average.

Сравнение c конкурентами

Изменение цены

CytomX Therapeutics Inc Прогноз

Целевая цена

By TipRanks

285.54% рост

Прогноз на 12 месяцев

Средняя 12.8 USD  285.54%

Максимум 16 USD

Минимум 11 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для CytomX Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

5

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

160 / 340Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
help-icon Live chat